A new ray of hope is there for the people who frequently suffer from asthma, rheumatoid arthritis or are susceptible to allergies or other inflammatory diseases.

A new study conducted by researchers at ‘Barts’ and ‘The London School of Medicine and Dentistry’ has found a key component of the body’s own responses to allergens. Allergens are the substances that cause the immunity system of the body to trigger a fight against the foreign bodies. These foreign bodies could be just dust, pollen, peanut, milk, penicillin etc. and since they are not recognized by our immune system, body reacts to them. The symptoms occur in the form of inflamed airway or runny nose or itching in the eyes or rashes on the skin. So this key component which triggers this fight can be targeted to reduce the allergic reactions.

In contrary to the all the major treatments for asthma and allergies which target on reducing symptoms , this new study targets the immune system of the body.

As most of the allergies are mere responses of our immune system to the foreign elements, they can be avoided if the immune system is slowed down. However this involves a risk. The person may be left prone to infection since there would be no immunity to fight. So this treatment could be administered only in the extreme cases. The conventional treatment would continue focusing on managing the symptoms of allergy.

This limitation has been ruled out by the BBSRC team led by Professor Bart Vanhaesebroeck who has proven in its study that the allergic reaction can be hampered before the occurrence of the symptoms without affecting the immune system of the body by aiming at “p110delta”.

“P110delta” is a molecule, belonging to the family of eight proteins called ‘PI3Ks’.  These proteins control various biological functions of the body. Their involvement in various diseases including cancer makes them an important target for further research and development in producing an effective drug to combat these ailments.

The researchers tried to go behind the specific diseases associated with the eight members of the ‘PI3Ks’ proteins so that specific drugs could be developed with reduced side effects. They brought in use various genetic techniques to determine this.

In the recent study, the research confirmed that ‘p110delta’ is found to be playing more important role in allergic reactions than ‘p110gamma’, another member of the ‘PI3K’ family. So now they can be targeted to develop ‘p110delta’ blockers. Soon their clinical use can be expected to enter in the human arena.

Dr Khaled Ali, the lead researcher informed that ‘p110delta’, identified in 1997 had many apprehensions associated with it. However, the recent work has shown its ability to control the body’s reaction to an allergen and thus prevent the symptoms to occur.

This study has already confirmed that ‘p110delta’ is the key player among the ‘PI3K’ molecules. So Professor Vanhaesebroeck is quite hopeful that a drug could be developed very soon to combat the problem of allergies and a therapy could be devised for not only controlling the symptoms which occur in the body but also would be able to target the real causes.

This study promises to get a revolutionary way to fight against the allergies which cause misery to millions of human beings.

This article is the property of http://www.Healthpm.com
Copying and publishing any article from our site is strictly NOT allowed.